Market Analysis Report Pediatrics Medicine Market 2019 | Page 2

market is one of the important segments in the pharmaceutical industry. Infants are prone to infections
owing to their under-developed immune system.
The pediatric medicines market is one of the emerging markets in the pharmaceutical sphere with huge
unmet needs and requires support for better innovation and higher R&D investments. In addition, rising
incidence of disease conditions such as obesity, diabetes and hypertension in children have also
contributed in its growth. Despite various developments, low disposable income and unawareness in
developing nations are hindering the growth of this market. Moreover, side effects such as anxiety,
headache and fatigue are also restricting its growth.
Pediatrics Medicine Market Covers the Table of Contents With Segments, Key Players And Region. Based
on Product Type, Pediatrics Medicine Market is sub segmented into Enteral and Parenteral. On the Basis
of Application, Market is sub segmented into Respiratory diseases, Infectious diseases, Gastrointestinal
diseases, CNS diseases, Oncological diseases.
Major Players profiled in the Pediatrics Medicine Market report incorporate: GSK, Novartis, Pfizer,
Sanofi, Abbott, Bristol-Myers Squibb, Cipla, Eisai Pharmaceuticals, Eli Lilly, F. Hoffman-La Roche,
Glenmark, Helsinn Healthcare, Heron Therapeutics, Ipca Laboratories, Lupin Pharmaceuticals, Merck
Sharp & Dohme, RedHill, Sun Pharmaceutical Industries, Takeda Pharmaceutical.
Industry News:
GSK today announced it has received approval from the US Food and Drug Administration (FDA) for the
use of Arnuity Ellipta (fluticasone furoate) a once-daily inhaled corticosteroid (ICS) medicine for the
maintenance treatment of asthma in children from as young as 5 years. This makes Arnuity one of the
few once-daily treatments for asthma licenced in the US in this younger age group, where there remains
a significant need for convenient and effective treatment options.
AveXis, a Novartis company, today announced the US Food and Drug Administration (FDA) has approved
Zolgensma® (onasemnogene abeparvovec-xioi) for the treatment of pediatric patients less than 2 years
of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1
(SMN1) gene. Zolgensma is designed to address the genetic root cause of SMA by providing a functional
copy of the human SMN gene to halt disease progression through sustained SMN protein expression
with a single, one-time intravenous (IV) infusion. Zolgensma is the first and only gene therapy approved
by the FDA for the treatment of SMA, including those who are pre-symptomatic at diagnosis.
Request a Discount on standard prices of this premium report @
https://www.businessindustryreports.com/check-discount/162806 .
Region segment: This report is segmented into several key regions, with sales, revenue, market share
(%) and growth Rate (%) of Pediatrics Medicine in these regions, from 2014 to 2023 (forecast), covering:
North America, Europe, Asia Pacific, Middle East & Africa and South America.
Significant points in table of contents: Market Definition, Market Overview, Business Introduction,
Segmentation (Region Level), Segmentation (Type Level), Segmentation (Industry Level), Segmentation